{
  "MARI.VI": {
    "city": "Korneuburg",
    "country": "Austria",
    "currency": "EUR",
    "exchange": "VIE",
    "industry": "Biotechnology",
    "long_name": "Marinomed Biotech AG",
    "market": "at_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MARINOMED BIOTECH AG",
    "state": null,
    "summary": "Marinomed Biotech AG, a biopharmaceutical company, develops products for respiratory and ophthalmological diseases in Austria, other European countries, and internationally. It operates through two segments, Carragelose and Marinosolv. The company develops its products based on the Marinosolv, a technology platform that enhances the bioavailability of hardly soluble compounds for the treatment of sensitive tissues, such as eyes, nose, lung, and gastrointestinal tract; and Carragelose, an antiviral respiratory technology platform for the treatment of respiratory tract viral infections, including SARS-Cov-2, as well as offers nasal and throat sprays, and lozenges. It is also developing Budesolv and Tacrosolv targeting inflammatory diseases of nose and eyes; and Flutisolv, a nasal spray for allergic rhinitis. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.",
    "website": "http://www.marinomed.com",
    "zipcode": "2100"
  },
  "MBG.F": {
    "city": "Korneuburg",
    "country": "Austria",
    "currency": "EUR",
    "exchange": "FRA",
    "industry": "Biotechnology",
    "long_name": "Marinomed Biotech AG",
    "market": "dr_market",
    "market_cap": "Micro Cap",
    "sector": "Healthcare",
    "short_name": "MARINOMED BIOTECH AG INH.",
    "state": null,
    "summary": "Marinomed Biotech AG, a biopharmaceutical company, develops products for respiratory and ophthalmological diseases in Austria, other European countries, and internationally. It operates through two segments, Carragelose and Marinosolv. The company develops its products based on the Marinosolv, a technology platform that enhances the bioavailability of hardly soluble compounds for the treatment of sensitive tissues, such as eyes, nose, lung, and gastrointestinal tract; and Carragelose, an antiviral respiratory technology platform for the treatment of respiratory tract viral infections, including SARS-Cov-2, as well as offers nasal and throat sprays, and lozenges. It is also developing Budesolv and Tacrosolv targeting inflammatory diseases of nose and eyes; and Flutisolv, a nasal spray for allergic rhinitis. The company was formerly known as Marinomed Biotechnologie GmbH and changed its name to Marinomed Biotech AG in June 2017. Marinomed Biotech AG was incorporated in 2006 and is headquartered in Korneuburg, Austria.",
    "website": "http://www.marinomed.com",
    "zipcode": "2100"
  }
}
